Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Lebanon: A recent study analyzing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

By December 2023, 12.3% of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.